Literature DB >> 17351431

Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.

Natsuko Tsuda1, Masahiro Okada, Takamichi Murakami.   

Abstract

RATIONALE AND
OBJECTIVES: To investigate the potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for the differential diagnosis of nonalcoholic steatohepatitis (NASH) and fatty liver (FL).
METHODS: Twenty-one male rats were divided into 3 groups. Seven rats in the NASH group were fed a choline-deficient diet for 10 weeks, and the 7 rats in the FL group were fed a standard diet also containing 1% (wt/wt) orotic acid for 4 weeks. As a control, 7 rats were fed a standard diet. After the feeding period, all rats were subjected to contrast-enhanced dynamic and delayed MRI with a 2D-FLASH technique. Gd-DTPA (0.1 mmol Gd/kg) and Gd-EOB-DTPA (0.025 mmol Gd/kg) were injected into the tail vein at 24-hour intervals. Signal intensities of the liver were measured for each MR image and the relative enhancement (RE) was calculated. In addition, the time of maximum RE (Tmax) and the half-life of RE (T1/2) in liver were compared. After MRI, the liver was histologically analyzed to evaluate steatosis, hepatitis, and fibrosis.
RESULTS: Diffuse macrovesicular steatosis and severe fibrosis were observed in the NASH group, whereas diffuse microvesicular steatosis and rare fibrosis were observed in the FL group. Immediately after the Gd-DTPA injection, the RE in the liver of each group temporarily increased, and thereafter, rapid RE reduction was observed. However, a continuous increase and subsequent slow reduction of RE were induced after the Gd-EOB-DTPA injection. Although there was no difference between the Tmax and T1/2 of each group after the Gd-DTPA injection, Tmax and T1/2 of the NASH group were significantly prolonged in comparison with FL and control groups after the Gd-EOB-DTPA injection (P < 0.01).
CONCLUSIONS: It was possible to differentiate NASH and FL by evaluating the SI time course on Gd-EOB-DTPA enhanced MRI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351431     DOI: 10.1097/01.rli.0000258058.44876.a5

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  26 in total

1.  Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression.

Authors:  Natsuko Tsuda; Osamu Matsui
Journal:  Eur Radiol       Date:  2011-08-11       Impact factor: 5.315

2.  Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.

Authors:  O Dahlqvist Leinhard; N Dahlström; J Kihlberg; P Sandström; T B Brismar; O Smedby; P Lundberg
Journal:  Eur Radiol       Date:  2011-10-09       Impact factor: 5.315

3.  Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla.

Authors:  N Verloh; M Haimerl; F Zeman; M Schlabeck; A Barreiros; M Loss; A G Schreyer; C Stroszczynski; C Fellner; P Wiggermann
Journal:  Eur Radiol       Date:  2014-02-16       Impact factor: 5.315

4.  Correlation of liver parenchymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma.

Authors:  Kei Kubota; Taiji Tamura; Nobutaka Aoyama; Munenobu Nogami; Norihiko Hamada; Akihito Nishioka; Yasuhiro Ogawa
Journal:  Oncol Lett       Date:  2012-03-01       Impact factor: 2.967

5.  Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow.

Authors:  Sachiyo Kogita; Yasuharu Imai; Masahiro Okada; Tonsok Kim; Hiromitsu Onishi; Manabu Takamura; Kazuto Fukuda; Takumi Igura; Yoshiyuki Sawai; Osakuni Morimoto; Masatoshi Hori; Hiroaki Nagano; Kenichi Wakasa; Norio Hayashi; Takamichi Murakami
Journal:  Eur Radiol       Date:  2010-05-19       Impact factor: 5.315

6.  Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease.

Authors:  Ying Ding; Sheng-Xiang Rao; Tao Meng; Caizhong Chen; Renchen Li; Meng-Su Zeng
Journal:  Eur Radiol       Date:  2014-01-26       Impact factor: 5.315

7.  Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests.

Authors:  Guido M Kukuk; Stephanie G Schaefer; Rolf Fimmers; Dariusch R Hadizadeh; Samer Ezziddin; Ulrich Spengler; Hans H Schild; Winfried A Willinek
Journal:  Eur Radiol       Date:  2014-07-17       Impact factor: 5.315

8.  Age dependence of spleen- and muscle-corrected hepatic signal enhancement on hepatobiliary phase gadoxetate MRI.

Authors:  Simon Matoori; Johannes M Froehlich; Stefan Breitenstein; Aleksis Doert; Viktoria Pozdniakova; Dow-Mu Koh; Andreas Gutzeit
Journal:  Eur Radiol       Date:  2015-09-03       Impact factor: 5.315

Review 9.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.

Authors:  Raj Vuppalanchi; Naga Chalasani
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

Review 10.  Current Modalities for the Assessment of Future Remnant Liver Function.

Authors:  Fadi Rassam; Pim B Olthof; Roelof J Bennink; Thomas M van Gulik
Journal:  Visc Med       Date:  2017-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.